



NDA 209803/S-006  
NDA 209805/S-012  
NDA 209806/S-009

## **SUPPLEMENT APPROVAL**

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.  
Attention: Wendy L. Carofano, Pharm D, RPh, PMP  
Director, Global Regulatory Affairs  
126 E. Lincoln Avenue, P.O. Box 2000  
Mail Drop: RY34B-332  
Rahway, NJ 07065

Dear Dr. Carofano:

Please refer to your supplemental new drug applications (sNDAs) dated and received on July 29, 2022, and your amendments, submitted under section 505(b) and pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Steglatro (ertugliflozin) tablets, Steglujan (ertugliflozin and sitagliptin) tablets, and Segluromet (ertugliflozin and metformin hydrochloride) tablets.

We also refer to our letter dated July 1, 2022, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we have determined should be included in the labeling for sodium-glucose co-transporter 2 (SGLT2) inhibitors and lithium. This information pertains to the risk of a drug-drug interaction (DDI) associated with concomitant use of SGLT2 inhibitors and lithium.

These sNDAs provide for revisions to the labeling for Steglatro, Steglujan and Segluromet, consistent with our July 1, 2022, letter and the comments sent to you in our August 31, 2022, September 21, 2022, and September 26, 2022, correspondences.

### **APPROVAL & LABELING**

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-*

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

*Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.*<sup>3</sup>

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety-related information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety-related information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

### **PATENT LISTING REQUIREMENTS**

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

NDA 209803/S-006  
NDA 209805/S-012  
NDA 209806/S-009  
Page 4

If you have any questions, contact Georgia Rogers, Regulatory Project Manager, at [Georgia.Rogers@fda.hhs.gov](mailto:Georgia.Rogers@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Monika Houstoun, Pharm.D., M.P.H  
Deputy Director for Safety  
Division of Diabetes, Lipid Disorders, and Obesity  
Office of Cardiology, Hematology, Endocrinology,  
and Nephrology  
Office of New Drugs  
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Steglatro Prescribing Information
  - Steglatro Medication Guide
  - Steglujan Prescribing Information
  - Steglujan Medication Guide
  - Segluromet Prescribing Information
  - Segluromet Medication Guide

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

MONIKA A HOUSTOUN  
10/13/2022 09:21:42 AM